$ATOS
ATOSSA THERAPEUTICS, INC.

2021 Q4 Form 10-Q Financial Statement

#000143774921026640 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.001M $2.952M $1.850M
YoY Change 60.49% 59.59% 14.91%
% of Gross Profit
Research & Development $1.827M $2.206M $1.659M
YoY Change -22.6% 32.98% -1.49%
% of Gross Profit
Depreciation & Amortization $1.730K $6.220K $20.00K
YoY Change -82.7% -68.9% 100.0%
% of Gross Profit
Operating Expenses $4.828M $5.159M $3.509M
YoY Change 14.13% 47.02% 6.39%
Operating Profit -$5.159M -$3.509M
YoY Change 47.02% 6.39%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$3.630K -$38.55K $17.75K
YoY Change -99.89% -317.25% 44.46%
Pretax Income -$4.832M -$5.197M -$3.491M
YoY Change -35.41% 48.87% 6.24%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.832M -$5.197M -$3.491M
YoY Change -35.41% 48.87% 6.24%
Net Earnings / Revenue
Basic Earnings Per Share -$0.04
Diluted Earnings Per Share -$38.12K -$41.07K -$343.5K
COMMON SHARES
Basic Shares Outstanding 126.6M 126.6M 10.40M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $136.4M $140.0M $9.100M
YoY Change 244.39% 1438.91% -40.52%
Cash & Equivalents $136.4M $140.0M $9.106M
Short-Term Investments
Other Short-Term Assets $1.193M $18.06K $178.9K
YoY Change 81.58% -89.91% 8568.17%
Inventory
Prepaid Expenses $2.488M $1.883M $1.484M
Receivables
Other Receivables
Total Short-Term Assets $141.2M $143.0M $11.32M
YoY Change 230.23% 1163.32% -30.99%
LONG-TERM ASSETS
Property, Plant & Equipment $20.00K $22.14K $25.43K
YoY Change -4.76% -12.94% -35.03%
Goodwill
YoY Change
Intangibles $54.00K
YoY Change 31.71%
Long-Term Investments
YoY Change
Other Assets $22.00K $13.41K $17.22K
YoY Change 29.41% -22.13% 0.0%
Total Long-Term Assets $22.00K $36.76K $119.3K
YoY Change -68.12% -69.2% -39.08%
TOTAL ASSETS
Total Short-Term Assets $141.2M $143.0M $11.32M
Total Long-Term Assets $22.00K $36.76K $119.3K
Total Assets $141.3M $143.0M $11.44M
YoY Change 229.75% 1150.46% -31.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.717M $668.0K $682.6K
YoY Change 8.06% -2.14% 36.13%
Accrued Expenses $204.0K $75.70K $85.17K
YoY Change 119.35% -11.13% -62.22%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.126M $1.676M $1.565M
YoY Change -80.05% 7.06% 0.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.126M $1.676M $1.565M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.126M $1.676M $1.567M
YoY Change -80.05% 6.97% -0.74%
SHAREHOLDERS EQUITY
Retained Earnings -$129.2M -$124.4M -$104.4M
YoY Change 15.49% 19.14% 14.17%
Common Stock $266.8M $265.2M $113.7M
YoY Change 92.7% 133.29% 7.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $138.1M $141.3M $9.871M
YoY Change
Total Liabilities & Shareholders Equity $141.3M $143.0M $11.44M
YoY Change 229.75% 1150.46% -31.08%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$4.832M -$5.197M -$3.491M
YoY Change -35.41% 48.87% 6.24%
Depreciation, Depletion And Amortization $1.730K $6.220K $20.00K
YoY Change -82.7% -68.9% 100.0%
Cash From Operating Activities -$3.665M -$3.062M -$2.680M
YoY Change 6.86% 14.24% 51.41%
INVESTING ACTIVITIES
Capital Expenditures $400.00 -$9.400K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $400.00 -$9.400K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 720.0 678.9K 4.320M
YoY Change -100.0% -84.28%
NET CHANGE
Cash From Operating Activities -3.665M -3.062M -2.680M
Cash From Investing Activities 400.0 -9.400K 0.000
Cash From Financing Activities 720.0 678.9K 4.320M
Net Change In Cash -3.664M -2.392M 1.640M
YoY Change -112.03% -245.85% -192.66%
FREE CASH FLOW
Cash From Operating Activities -$3.665M -$3.062M -$2.680M
Capital Expenditures $400.00 -$9.400K $0.00
Free Cash Flow -$3.666M -$3.052M -$2.680M
YoY Change 6.87% 13.89% 51.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
225000
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
126624110
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
584
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
584
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
621
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
621
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
126623541
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
126623541
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47548835
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47548835
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
178544 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
133157 USD
CY2021Q1 atos Issuance Of Common Stock And Warrants Issuance Costs
IssuanceOfCommonStockAndWarrantsIssuanceCosts
5493310 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 USD
CY2020Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2020Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
0 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
699410
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.46
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.40
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
140040955 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39553671 USD
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
110000 USD
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1883197 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1813902 USD
CY2021Q3 atos Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
934672 USD
CY2020Q4 atos Research And Development Tax Rebate Receivable
ResearchAndDevelopmentTaxRebateReceivable
634940 USD
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
18060 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
657662 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
142986884 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
42770175 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22138 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20632 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
13375 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1217 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18053 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13408 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
17218 USD
CY2021Q3 us-gaap Assets
Assets
143023647 USD
CY2020Q4 us-gaap Assets
Assets
42839453 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
667988 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1588613 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
75695 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
93367 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
912670 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
963665 USD
CY2021Q3 atos Common Stock Warrant Lability
CommonStockWarrantLability
0 USD
CY2020Q4 atos Common Stock Warrant Lability
CommonStockWarrantLability
13003075 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1217 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18053 USD
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
18251 USD
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4748 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1675821 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15671521 USD
CY2021Q3 us-gaap Liabilities
Liabilities
1675821 USD
CY2020Q4 us-gaap Liabilities
Liabilities
15671521 USD
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
1 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
1 USD
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
22792225 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
8558778 USD
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
242373694 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
129887146 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-124402093 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111898992 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
141347826 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27167932 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
143023647 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42839453 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2206158 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1659075 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7383281 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4250934 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2952436 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1849741 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8309807 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6130698 USD
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
5158594 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
3508816 USD
us-gaap Operating Expenses
OperatingExpenses
15693088 USD
us-gaap Operating Expenses
OperatingExpenses
10381632 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5158594 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3508816 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-15693088 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-10381632 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-38551 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17745 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-81374 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
36999 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5197145 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3491071 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15774462 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10344633 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-5197145 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3491071 USD
us-gaap Net Income Loss
NetIncomeLoss
-15774462 USD
us-gaap Net Income Loss
NetIncomeLoss
-10344633 USD
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.09
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
126537544
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10162770
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
113689961
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9496222
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
13156005 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
687752 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2947420 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
10896337 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
347627 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1036484 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-3906142 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
8374306 USD
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4338671 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
541100 USD
CY2020Q3 atos Stock Repurchased During Period For Stock Option Exercise And Taxes Value
StockRepurchasedDuringPeriodForStockOptionExerciseAndTaxesValue
555522 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
663593 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3491071 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
9871077 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27167932 USD
CY2021Q1 atos Common Stock And Warrants Issued During Period Value New Issues
CommonStockAndWarrantsIssuedDuringPeriodValueNewIssues
69668408 USD
CY2021Q1 atos Stock Issued During Period Value Warrant Exercised
StockIssuedDuringPeriodValueWarrantExercised
32760302 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
639751 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3538069 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-920625 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
139701399 USD
CY2021Q2 atos Stock Issued During Period Value Warrant Exercised
StockIssuedDuringPeriodValueWarrantExercised
10195641 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1214110 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-7039248 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
144071902 USD
CY2021Q3 atos Common Stock And Warrants Issued During Period Value New Issues
CommonStockAndWarrantsIssuedDuringPeriodValueNewIssues
862466 USD
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1722573 USD
CY2021Q3 atos Stock Repurchased During Period For Stock Option Exercise And Taxes Value
StockRepurchasedDuringPeriodForStockOptionExerciseAndTaxesValue
1906108 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1794138 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-5197145 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
141347826 USD
us-gaap Net Income Loss
NetIncomeLoss
-15774462 USD
us-gaap Net Income Loss
NetIncomeLoss
-10344633 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
3647999 USD
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2387829 USD
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-0 USD
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-4149 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21265 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
37265 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
69295 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
621907 USD
atos Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
299732 USD
atos Increase Decrease In Research And Development Tax Rebate Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxRebateReceivable
-300451 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-643412 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
152781 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
389441 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-17672 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7285 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-50995 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-146573 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
13503 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1779 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12806602 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8137695 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9396 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9367 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9396 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9367 USD
atos Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
0 USD
atos Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
4686298 USD
atos Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
69668408 USD
atos Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
0 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
574867 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
14422 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
391332 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
43818409 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
113303282 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4671876 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
100487284 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3475186 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39663671 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12691136 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
140150955 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9215950 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
140040955 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9105950 USD
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 USD
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
140150955 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9215950 USD
us-gaap Stock Issued1
StockIssued1
1331241 USD
us-gaap Stock Issued1
StockIssued1
541100 USD
atos Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
13003075 USD
atos Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
0 USD
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTE <em style="font: inherit;">1:</em> NATURE OF OPERATIONS</b></p> <p style="margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> January 6, 2020, </em>we changed our corporate name from Atossa Genetics Inc. to Atossa Therapeutics, Inc.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt;">Atossa Therapeutics, Inc. (the “Company”) was incorporated on <em style="font: inherit;"> April 30, 2009, </em>in the State of Delaware. The Company was initially formed to develop and market medical devices, laboratory tests and therapeutics to address breast health conditions. The Company is currently developing its pharmaceuticals in the fields of oncology and infectious disease with a focus on treatments of the novel coronavirus ("COVID-<em style="font: inherit;">19"</em>), breast cancer and other breast conditions. The Company’s fiscal year ends on <em style="font: inherit;"> December 31.</em></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 21.45pt 0pt -18pt; text-align: justify; text-indent: 18pt;"><b>Impact of the Novel Coronavirus </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: -9pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The continued spread of the COVID-<em style="font: inherit;">19</em> pandemic is affecting the United States and global economies and <em style="font: inherit;"> may </em>affect the Company’s operations and those of <em style="font: inherit;">third</em> parties on which the Company relies, including causing possible disruptions in the supply of the Company’s Endoxifen, AT-<em style="font: inherit;">H201,</em> AT-<em style="font: inherit;">301</em> and the conduct of current and future clinical trials. In addition, the COVID-<em style="font: inherit;">19</em> pandemic <em style="font: inherit;"> may </em>affect the operations of the U.S. FDA and other health authorities including similar entities/agencies in Sweden and Australia, which could result in delays in meetings, reviews and approvals. The evolving COVID-<em style="font: inherit;">19</em> pandemic could also directly or indirectly impact the pace of enrollment in our clinical trials for at least the next several months and possibly longer as patients <em style="font: inherit;"> may </em>avoid or <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be able to travel to healthcare facilities and physicians’ offices except for a health emergency. Such facilities and offices <em style="font: inherit;"> may </em>also be required to focus limited resources on non-clinical trial activities, including treatment of COVID-<em style="font: inherit;">19</em> patients, and <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be available, in whole or in part, for clinical trial activities related to the Company's products under development. We have <em style="font: inherit;">not</em> experienced any delay in drug supply for our ongoing and planned clinical studies, including studies of Endoxifen, AT-<em style="font: inherit;">301</em> and AT-<em style="font: inherit;">H201.</em> However, our Phase <em style="font: inherit;">2</em> clinical study of Endoxifen that was being conducted in Australia was enrolling slower than expected due in part to COVID-<em style="font: inherit;">19</em> restrictions. The study site we plan to use in Sweden has been negatively impacted by COVID-<em style="font: inherit;">19</em> restrictions which must be lifted before we can begin our study there. As a result, the study in Stockholm could be delayed or enroll more slowly than expected. Additionally, while the potential economic impact brought by, and the duration of, the COVID-<em style="font: inherit;">19</em> pandemic is difficult to assess or predict, the impact of the COVID-<em style="font: inherit;">19</em> pandemic on the global financial markets <em style="font: inherit;"> may </em>reduce the Company’s ability to access capital, which could negatively impact the Company’s short-term and long-term liquidity. The ultimate impact of the COVID-<em style="font: inherit;">19</em> pandemic is highly uncertain and subject to change. We do <em style="font: inherit;">not</em> yet know the full extent of potential delays or impacts on our business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material adverse impact on the Company’s liquidity, capital resources, operations, financial position and business and those of the <em style="font: inherit;">third</em> parties on which we rely. We will continue to monitor future enrollment in studies for potential restrictions on site visits, mammograms or the impositions of new restrictions on trials as a result of the COVID-<em style="font: inherit;">19</em> pandemic.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 36pt;">In response to the COVID-<em style="font: inherit;">19</em> pandemic, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law on <em style="font: inherit;"> March 27, 2020. </em>On <em style="font: inherit;"> March 11, 2021, </em>President Biden signed an additional coronavirus relief package entitled the American Rescue Plan Act of <em style="font: inherit;">2021,</em> which included, among other things, provisions relating to stimulus payments to some Americans, extension of several CARES Act relief programs, expansion of the child tax credit, funding for vaccinations and other COVID-<em style="font: inherit;">19</em> related assistance programs. The CARES Act and the American Rescue Plan Act have <em style="font: inherit;">not</em> had a material impact on the Company; however, we will continue to examine the impacts that the CARES Act and the American Rescue Plan Act, as well as any future economic relief legislation, <em style="font: inherit;"> may </em>have on our business.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"> </p>
us-gaap Net Income Loss
NetIncomeLoss
-15774462 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12806602 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
140040955 USD
CY2021Q3 atos Working Capital Deficit
WorkingCapitalDeficit
141311063 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
113486817 USD
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Use of Estimates</b></p> <p style="margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </p> <p style="margin: 0pt; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"> </p>
CY2020Q4 atos Common Stock Warrant Lability
CommonStockWarrantLability
13003075 USD
CY2021Q1 atos Common Stock Warrant Lability
CommonStockWarrantLability
0 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
129887146 USD
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
139618860 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111898992 USD
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-108627631 USD
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
110000 USD
CY2021Q3 atos Research And Development Current
ResearchAndDevelopmentCurrent
1567871 USD
CY2020Q4 atos Research And Development Current
ResearchAndDevelopmentCurrent
1215834 USD
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
136880 USD
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
417854 USD
CY2021Q3 atos Professional Services Current
ProfessionalServicesCurrent
131197 USD
CY2020Q4 atos Professional Services Current
ProfessionalServicesCurrent
128229 USD
CY2021Q3 atos Financial Exchange Fees Accrued Current
FinancialExchangeFeesAccruedCurrent
14500 USD
CY2020Q4 atos Financial Exchange Fees Accrued Current
FinancialExchangeFeesAccruedCurrent
0 USD
CY2021Q3 us-gaap Deposit Assets
DepositAssets
14218 USD
CY2020Q4 us-gaap Deposit Assets
DepositAssets
14218 USD
CY2021Q3 us-gaap Prepaid Rent
PrepaidRent
9360 USD
CY2020Q4 us-gaap Prepaid Rent
PrepaidRent
4488 USD
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
9171 USD
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
33279 USD
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1883197 USD
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1813902 USD
CY2021Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
631394 USD
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
689635 USD
CY2021Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
173430 USD
CY2020Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
171112 USD
CY2021Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
107846 USD
CY2020Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
102918 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
912670 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
963665 USD
CY2021Q3 atos Number Of Shares Authorized To Issue
NumberOfSharesAuthorizedToIssue
185000000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.18
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
22276844
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
22276844
CY2021Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
862466 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
43818409 USD
CY2021Q3 atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
296000
atos Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
37452000
CY2021Q3 atos Stock Issued During Period Shares Warrant Exercised
StockIssuedDuringPeriodSharesWarrantExercised
296000
atos Stock Issued During Period Shares Warrant Exercised
StockIssuedDuringPeriodSharesWarrantExercised
37452000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5197145 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3491071 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15774462 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10344633 USD
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
126537544
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10162770
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
113689961
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9496222
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.09
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
32565822
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8405977
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33629683
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7078654
CY2021Q3 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
0 USD
CY2021Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
139850220 USD
CY2020Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
39345260 USD
atos Lessee Operating Lease Monthly Rent Payments
LesseeOperatingLeaseMonthlyRentPayments
750 USD
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
3500 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
16800 USD
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
14200 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
46300 USD
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.113 pure
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1200 USD
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
3700 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
18100 USD
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
12900 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
42300 USD
CY2021Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
6931 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
19100 USD
CY2020Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
4488 USD
us-gaap Short Term Lease Cost
ShortTermLeaseCost
13251 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
175000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3818921
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
225000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3140000
CY2021Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
699410
CY2021Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.46
CY2020Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
225000
CY2020Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.40
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1794138 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
663593 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3647999 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2387829 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7067436
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.74
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3818921
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.98
atos Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
99800 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
699410
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2753652 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
75000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
223
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
225.00
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10111724
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.84
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M10D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11697962 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5663935
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.94
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y10M13D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9039985 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
10111724
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.84
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M10D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
11697962 USD
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
4447789

Files In Submission

Name View Source Status
0001437749-21-026640-index-headers.html Edgar Link pending
0001437749-21-026640-index.html Edgar Link pending
0001437749-21-026640.txt Edgar Link pending
0001437749-21-026640-xbrl.zip Edgar Link pending
atos-20210930.xsd Edgar Link pending
atos-20210930_cal.xml Edgar Link unprocessable
atos-20210930_def.xml Edgar Link unprocessable
atos-20210930_lab.xml Edgar Link unprocessable
atos-20210930_pre.xml Edgar Link unprocessable
atos20210930_10q.htm Edgar Link pending
atos20210930_10q_htm.xml Edgar Link completed
ex_280612.htm Edgar Link pending
ex_280613.htm Edgar Link pending
ex_280614.htm Edgar Link pending
ex_280615.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending